Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02399033
Recruitment Status : Unknown
Verified February 2015 by Shuqun Cheng, Eastern Hepatobiliary Surgery Hospital.
Recruitment status was:  Recruiting
First Posted : March 26, 2015
Last Update Posted : March 26, 2015
Sponsor:
Information provided by (Responsible Party):
Shuqun Cheng, Eastern Hepatobiliary Surgery Hospital

Brief Summary:

Study Objective: To evaluate the efficacy and safety of Xihuang Capsules prevention of recurrence in patients with hepatocellular carcinoma after hepatectomy.

Study Design: The study was A Multicenter, Randomized, Controlled, Open-Label, Parallel-Group Clinical Trial. Patients will be randomly assigned to Xihuang Capsules group or the control group by the proportion of 2: 1.

The total sample size: 1000 cases. Study Process: The study is divided into three phases: the screening phase, treatment phase, follow-up phase.To complete screening in two weeks, patients who fit the criteria were randomly assigned to Xihuang Capsules group or the control group.In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2g,bid), Continuously taking to cancer recurrence or death.Control group was not received Xihuang Capsules. In the first month to three years after treatment, Conducting visits for once every three months,to evaluate the efficacy and safety with hepatocellular carcinoma recurrence rate in the three years after hepatectomy as the primary outcome. When entering the follow-up phase, Keeping in touch with patients withdrew from the study for a clinic or telephone follow-up every three months.

From signing informed consent till the end of the study, inspecting the adverse events and concomitant medications for all subjects in each visit.


Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: Xihuang Capsules Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy: A Multicenter Randomized Controlled Trial
Study Start Date : June 2014
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : December 2019

Arm Intervention/treatment
No Intervention: the control group
Patients in Control group were not received Xihuang Capsules.
Experimental: Xihuang Capsules group
Patients in Xihuang Capsules group were received Xihuang Capsules (2g, bid), Continuously taking to cancer recurrence or death.
Drug: Xihuang Capsules
In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
Other Name: Wangbang Pharmaceutical Xihuang Capsules




Primary Outcome Measures :
  1. Hepatocellular carcinoma recurrence rate in the three years after hepatectomy [ Time Frame: in the three years after hepatectomy ]
    Diagnostic criteria for hepatocellular carcinoma recurrence: refer to Chinese Anti-Cancer Association Professional Committee of hepatocellular carcinoma developed diagnostic criteria for primary hepatocellular carcinoma belong to Guangzhou standard in 2001. Once new or suspected place nature lesions within liver were found by B-ultrasonography examination,we should do CT, MRI or PET-CT review, in order to confirm the diagnosis. If imaging is positive, diagnosing hepatocellular carcinoma(dominant) recurrence after treatment; if imaging is negative, but AFP values> 400μg/L or ongoing elevated AFP values, diagnosing hepatocellular carcinoma occult recurrence after treatment.


Secondary Outcome Measures :
  1. Hepatocellular carcinoma recurrence rate in a year after hepatectomy [ Time Frame: in a year after hepatectomy ]
  2. Relapse free survival (RFS) [ Time Frame: up to 5 years ]
    RFS is defined as from date of randomization until the date of first documented tumor recurrence or date of death from any cause, whichever came first.

  3. Hepatocellular carcinoma survival rate in a year or three years after hepatectomy [ Time Frame: in a year or three years after hepatectomy ]
  4. Overall survival(OS) [ Time Frame: up to 5 years ]
    OS is defined as from date of randomization until the date of documented death from any cause.

  5. Improvement in quality of life in a year or three years after hepatectomy [ Time Frame: in a year or three years after hepatectomy ]

    Using Karnofsky-Performance-Status score:

    Evaluation Methods: Comparison of symptom scores before and after the treatment.

    Markedly: increasing by more than 20 points after treatment compared to before treatment; Effective: increasing by more than 10 points after treatment compared to before treatment; Stable: increasing by less than 10 points or no change after treatment compared to before treatment; Invalid: decrease after treatment than before treatment.


  6. number of participants with improvement of clinical symptoms, Such as flank pain, bloating, fatigue, anorexia and other syndromes of traditional Chinese Medicine. [ Time Frame: participants will be followed for the duration of study, an expected average of 3 months. ]

    Evaluation index : according to clinical observations, TCM symptoms are divided into 4 levels: (0) no symptoms, (1) mild, (2) moderate, (3)severe, Recording treatment according to symptoms.

    Evaluation methods: comparison of symptom total integral before and after the treatment (before treatment / after treatment) Markedly: symptom disappeared, or symptom integral reduce ≥ 2/3; Effective: symptom alleviative, integral is reduced≥1/3,≤2/3; Invalid: symptom is not alleviated or reduced<1/3.


  7. The incidence of adverse reaction. [ Time Frame: up to 5 years ]
    Classification according to the Common Terminology Criteria Adverse Events Version 4.0(CTCAE v4.0).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: 20-70 years old;
  2. Gender: male or female;
  3. clinical or pathological diagnosis of hepatocellular carcinoma (HCC) in previously untreated patients;
  4. The expected survival> 3 months;
  5. Child-Pugh grade in A-level;
  6. KPS score with 50-100 points;
  7. In two weeks after hepatectomy for R0 resection surgery. Preoperative must meet the following criteria:

    • BCLC stage of 0-B;
    • conform to the indications of hepatectomy;
    • Viable tumor resection confirmed by two highly qualified surgical doctors;
    • No other surgical contraindications.
  8. women in the reproductive period must be completely contraception in 28 days before treatment, during the treatment process and in 28 days after treatment;
  9. Men must be completely contraception and prohibited donation and sperm donation during the treatment process and in 28 days after treatment;
  10. All patients must be prohibited donation during the treatment process and in 28 days after treatment;
  11. In addition to the subjects, prohibitting other people taking this product.
  12. patients have a good understanding and could coordinate with investigators for the trial.
  13. Patients enrolled in the trial should sign an informed consent form, to indicate understanding the purpose and procedure of the trial, and patients volunteering to participate in the trial.

Exclusion Criteria:

  1. Because of suffering from any serious illness,laboratory abnormalities or mental abnormalities,the patient is unable to sign an informed consent form;
  2. patients with medical abnormalities may result in that the trial could not be evaluated or have security risks;
  3. persons who are unable to take oral drugs.
  4. coagulation dysfunction;
  5. HIV, syphilis-infected persons;
  6. persons who have a serious heart, liver and renal failure;
  7. persons who are known to allergic to the drug or any component of the drug;
  8. persons who are received experimental therapy in 28 days before the first treatment;
  9. persons who are received radiotherapy or other surgery(including of the other local surgery for cancer treatment,eg. TACE) in addition to hepatectomy in 14 days before the first treatment;
  10. lactating or pregnant women;
  11. patients in the reproductive period are unwilling or unable to contraception;
  12. persons with poor medication compliance;
  13. The researchers considered unsuitable selected patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02399033


Contacts
Layout table for location contacts
Contact: Shuqun Cheng, Ph.D 021-65564166

Locations
Layout table for location information
China, Shanghai
Eastern Hepatobiliary Surgical Hospital Recruiting
Shanghai, Shanghai, China, 200438
Contact: Shuqun Cheng, Ph.D    021-65564166      
Sponsors and Collaborators
Shuqun Cheng
Investigators
Layout table for investigator information
Principal Investigator: Shuqun Cheng, Ph.D Eastern Hepatobiliary Surgical Hospital
Layout table for additonal information
Responsible Party: Shuqun Cheng, Xihuang Capsules prevention of recurrence in patients with hepatocellular carcinoma after hepatectomy: A multicenter randomized controlled trial., Eastern Hepatobiliary Surgery Hospital
ClinicalTrials.gov Identifier: NCT02399033    
Other Study ID Numbers: SCheng
First Posted: March 26, 2015    Key Record Dates
Last Update Posted: March 26, 2015
Last Verified: February 2015
Keywords provided by Shuqun Cheng, Eastern Hepatobiliary Surgery Hospital:
Xihuang Capsules
hepatocellular carcinoma
Recurrence
hepatectomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Recurrence
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Disease Attributes
Pathologic Processes